We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RIO:ASXRio Tinto Limited Analysis

Data as of 2026-06-17 - not real-time

A$186.91

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Rio Tinto is trading at AU$186.91, comfortably above its 20‑day SMA (≈AU$185.65) and 50‑day SMA (≈AU$179.58), confirming a bullish trend direction. The RSI sits around 54, indicating neutral momentum, while the MACD histogram is negative, hinting at short‑term bearish pressure near the current resistance of AU$195.84. With a low beta of ~0.6 the stock is less volatile to market moves, yet 30‑day price volatility is high at roughly 32%, and the DCF fair‑value estimate of AU$43.3 suggests the shares are overvalued with a downside of about 6%.
Fundamentally, Rio delivers solid earnings: revenue of AU$57.6 bn grew 14.6% YoY, operating margin sits at 25% and ROE at 16%, supported by strong cash flow and a manageable debt profile. However, the company pays no dividend and analysts rate the stock as a “hold” amid extreme market greed sentiment. The diversified exposure to iron ore, aluminium, lithium and copper provides long‑term growth tails, but regulatory and ESG pressures remain a backdrop.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term moving averages
  • Negative MACD histogram indicating near‑term pressure
  • Proximity to resistance level with stable volume

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong revenue growth and operating margins
  • Robust cash generation versus moderate debt
  • Valuation gap between market price and DCF fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified exposure to growth commodities (copper, lithium, aluminium)
  • Long‑term demand trends for metals and ESG‑driven supply constraints
  • Solid balance sheet allowing continued capital investment

Key Metrics & Analysis

Financial Health

Revenue Growth14.60%
Profit Margin17.29%
P/E Ratio21.7
ROE16.40%
ROA7.86%
Debt/Equity35.43
P/B Ratio3.5
Op. Cash FlowA$16.8B
Free Cash FlowA$3.5B

Technical Analysis

TrendBullish
RSI54.5
SupportA$174.41
ResistanceA$195.84
MA 20A$185.65
MA 50A$179.58
MA 200A$150.69
MACDBearish
VolumeStable
Fear & Greed Index92.27

Valuation

Fair ValueA$43.29
Target PriceA$175.75
Upside/Downside-5.97%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.61
Volatility32.21%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.